The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended GlaxoSmithKline's Mekinist (trametinib) as a single agent treatment for melanoma with a BRAF V600 mutation. Mekinist is part of GSK's $16bn sale of its oncology division to Novartis through the mega asset swap deal announced earlier this week (scripintelligence.com, 22 April 2014).
Novartis is paying GSK $14.5bn up front and up to $1.5bn contingent on the results of the Phase III COMBI-d...